



SANUWAVE®

**Lytham Partners Virtual
Investor Conference**



June 24, 2020

Forward Looking Statements

This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective.

Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements.

Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

SANUWAVE Health

SANUWAVE Health, Inc. (SNWV) is an emerging shockwave technology company focused on the development and commercialization of patented noninvasive, high-energy, acoustic focused, shockwaves for the repair and regeneration of tissue, musculoskeletal and vascular structures.

**FDA permitted marketing of the
dermaPACE® System in
December 28, 2017**



Global Wound Care Market Overview

Medical burden of wounds drives new technology investments

US and worldwide wound prevalence

Types of wound	US prevalence (m)	Worldwide prevalence (m)	Healing time (days)	Estimated CAGR (2007-16e)
Surgical wounds	67	110.3	14	3.6%
Traumatic wounds	N/A	1.6	28	1.7%
Lacerations	N/A	20.4	14	1.2%
Burn wounds (outpatient)	1.3	3.4	21	1.0%
Burn wounds (medically treated)	N/A	6.5	21	1.3%
Burn wounds (hospitalised)	N/A	0.2	50	1.1%
Pressure ulcers	2.5	8.5	N/A	6.9%
Venous ulcers	2.5	12.5	N/A	6.7%
Diabetic ulcers	1.5	13.5	70-150	9.3%
Amputations	0.086	0.2	N/A	1.2%
Carcinomas	N/A	0.6	14	3.0%
Melanoma	N/A	0.1	14	3.2%
Complicated skin cancer	N/A	0.1	28	3.1%


Source: MedMarket Diligence (2015)

The increasing prevalence of chronic wounds is being driven by the sharp rise in diabetes and obesity

U.S. Wound Care Market Overview


Prevalence of wounds

**US prevalence of all wounds
(8 million pa)**



Source:
BioMedGPS (2015)

**U.S. prevalence of hard-to-heal wounds*
(3.2 million pa)**



Source: BioMedGPS (2015). Note: *<50% surface area reduction in four weeks

The dermaPACE® System Meets the Market Need for Better Outcomes at Lower Cost

KEY INDUSTRY NEEDS



**BROADER ACCESS
TO CARE**



REDUCED COSTS




**IMPROVED
HEALTH
OUTCOMES**



**BETTER PATIENT
CARE EXPERIENCE**

U.S. Market Strategy

>10 million



Placement

**x
\$200**

**x
Days**

**x
Rate**

=

REVENUE





SANUWAVE Health, Inc. Enters into Exclusive Letter of Intent to Acquire Celularity's UltraMIST[®] and Exclusive Partnership Rights for Wound Care Biologic Products



Broadens wound care platform with non-contact ultrasound device and human tissue biologic products that are complementary to SANUWAVE's dermaPACE[®] System



Provides end-to-end advanced wound care offerings that address the entire care pathway from the initial stages of treatment to wound closure




Enhances SANUWAVE's financial profile by adding significant revenue scale, increasing addressable markets and accelerating top-line growth

Transaction Rationale

Combination of SANUWAVE and Celularity's wound care assets would create a market-leading provider of advanced wound care solutions that improves clinical outcomes across the continuum of care

Investment Thesis



SANUWAVE at a Glance

Leading provider of FDA cleared focused shockwave technology for the treatment of diabetic foot ulcers

Company Snapshot

- SANUWAVE is a shockwave technology company that uses a patented system of noninvasive, high-energy, focused shockwaves for regenerative medicine
 - Lead product dermaPACE® is FDA cleared to treat diabetic foot ulcers and sold both domestically and around the world
 - More than 450 patients and 3,000+ treatments performed to-date
- The Company has a strong sales and clinical culture that builds relationships with leading KOL's, podiatrists, wound care RN's, hospitals, and wound care centers
 - 250+ clinicians certified to provide treatment with the dermaPACE System

Headquarters:	Suwanee, Georgia
Founded:	2005
Ownership:	Public (OTCQB: SNWV)
Headcount:	23
Target Customers:	<ul style="list-style-type: none"> Wound Care Centers Private Offices Hospitals Assisted living / SNFs
Device Placements:	130
Int'l Presence:	Product used in 10+ countries

2019 by the Numbers⁽¹⁾

450
Patients Treated

3,000
Treatments Performed

110
dermaPACE Systems
Shipped in 2019

250+
Clinicians
Certified & Trained

dermaPACE® Benefits



Robust closure with extremely low recurrence rate



Non-invasive, convenient and safe



Economic value for all constituents



May be used in combination with other modalities

Multiple Avenues to Drive Growth

**Further Penetrate
Large Addressable
Market**

**Expand to Adjacent
Wound Indications**

**Training Efforts to
Drive System Usage**

**Other Medical and
Non-Medical
Applications**


(1) SANUWAVE historical financials based on internal monthly financials.

The dermaPACE® System Overview


The dermaPACE® System positions SANUWAVE for continued success in large and emerging markets

Product Overview


- The dermaPACE® System is a **non-invasive device** for the repair and regeneration of skin, musculoskeletal tissue and vascular structures
- Developed to treat chronic wounds
- Utilizes **proprietary form** of high-energy, focused shockwave technology
- Therapy typically lasts 5-7 minutes
- Built on a wealth of medical and shockwave experience and state-of-the-art engineering
- Extensive clinical studies and tests have confirmed its safety and efficacy



Mechanism of Action



Perfusion & Arteriogenesis



Inflammatory Response



Growth Factor Upregulation



Angiogenesis

Indications for Use

FDA Approved



Diabetic Foot Ulcers

International



Diabetic Foot Ulcers



Post-Operative Wound Healing Defects



Post-Traumatic Wounds



Deep-Partial Thickness Burns



Decubitus Ulcers



Arterial Leg Ulcers



Venous Leg Ulcers

dermaPACE® activates biologic signaling and angiogenic responses, producing new vascularization, microcirculatory improvement and tissue regeneration

Celularity's Wound Care Portfolio at a Glance

Products focused on promoting natural healing and offering a clinically proven solution even in cases where standard of care has failed

Company Snapshot

<ul style="list-style-type: none"> Leading suite of natural wound healing products focused on early wound preparation and closure UltraMIST promotes early wound healing through a low-frequency, non-contact process from a self-contained device Interfyl and BIOVANCE products used to promote wound closure <ul style="list-style-type: none"> BIOVANCE provides a natural foundation and scaffold for wound healing and restoration of functional tissue Interfyl allows for cell adherence and growth during tissue repair Celularity owns and operates its own life banks, which allows them to control the process from biosourcing through advanced cell manufacturing and productization of biologics products 	Product Suite: <ul style="list-style-type: none"> Device that preps wound bed and promotes healing Biologics for wound closure
	Customers: 929 UltraMIST customers
	Customer Base: <ul style="list-style-type: none"> Hospitals Wound Care Centers VA Private Office Nursing Homes & Rehab Facilities
	States Served: 46

Product Portfolio


UltraMIST Platform



UltraMIST



Single Use Applicator




BIOVANCE



Interfyl

Regenerative Focused Products



BIOVANCE®
Human Amniotic Membrane Allograft

Interfyl®
Human Connective Tissue Matrix

Natural wound healing suite of products

UltraMIST Overview


UltraMIST expands SANUWAVE's addressable market with treatment of additional acute and chronic wounds

Product Overview

- A **low-frequency, non-contact ultrasound energy** delivered through a fluid mist
- UltraMIST is unique because the device **never touches the wound surface, making it pain-free**
- Device is self-contained making it easy to set-up, operate and store
- UltraMIST Therapy System includes a generator, treatment wand, and applicator
- Applicators provided in a case of twelve single-use (per patient) disposable applicators

Mechanism of Action

- 1 Delivers ultrasonic energy
- 2 Creates micro-strains
- 3 Micro-strains promote healing



FDA Approved Indications



Diabetic Foot Ulcers



Pressure Ulcers



Venous Leg Ulcers



Deep Tissue Pressure Injuries



Surgical Wounds

UltraMIST Therapy Systems produce a low energy ultrasound-generated mist used to promote wound healing through wound cleansing and maintenance debridement by the removal of fibrin, yellow slough, tissue exudates and bacteria


Celularity's Biologic Products

BIOVANCE®

| Human Amniotic Membrane Allograft

Overview

- Provides a natural foundation for wound healing
- Key cells and proteins move into the BIOVANCE material promoting tissue regeneration and wound healing
- Serves as intact extracellular matrix required for appropriate healing



Easy application and wound visualization

- Flexible – conforms to irregular surfaces
- Adaptable – self-adheres but can be sutured, taped, stapled, or glued
- Bidirectional – can be applied with either side facing the wound

Easy storage and preparation

- 5-year shelf life eliminates need for pre-ordering
- Room temperature storage – no refrigeration necessary
- No thawing, rinsing, or soaking required
- Available in multiple sizes for application flexibility

Interfyl®

| Human Connective Tissue Matrix

Overview

- Replaces damaged integumental soft tissue
- Augments / supplements inadequate connective tissues
- Repairs small surgical defects including exposed vital structures (bone, tendon, ligament, or nerve)




Adaptable filler of decellularized connective tissue matrix

- Can fill irregular spaces or soft tissue deficits
- Allows for cell adherence and growth during tissue repair
- Consists of natural structural and biochemical extracellular matrix components
- Provides structural support while maintaining elasticity

Available in both flowable and particulate forms

- 1.5mL flowable format in 3-mL syringe
- 50mg and 100mg particulates in vial

SANUWAVE Would Address Entire Advanced Wound Care Continuum



dermaPACE® reduces amputation rate of advanced DFUs by more than 2.5x from ~6.6% to ~2.3%⁽¹⁾

(1) FDA trial results comparing dermaPACE therapy vs. a control group.

Foundation for Sustained Growth

Building on a strong foundation, SANUWAVE would have multiple avenues to drive continued, sustained growth



Other Medical and Non-Medical Applications

- Capitalize on other medical markets – orthopedics, pain, plastic surgery, and vascular / cardiac
- Expand into non-medical applications – have existing relationship with NASA

Other Applications



Strong Advanced Wound Care Pipeline

- Continued R&D investment to drive product enhancements and innovative new products to meet needs and volume of market
- Sustainable Biologics product pipeline

Strong Advanced Wound Care Pipeline

Innovative solutions to improve patient outcomes



Expand U.S. Addressable Market

- \$45B of addressable market through adjacent wound indications
- Target indications: Venus Leg Ulcers, Pressure Ulcers, Deep Tissue Pressure Injuries, Surgical Wounds

Expand U.S. Addressable Market

No product updates required

Existing relationships create natural sales channel



UltraMIST International Commercialization

- Strong network of international joint venture partners and distributors
- Leverage dermaPACE® market awareness to drive UltraMIST

Commercialize UltraMIST Internationally

Strong interest from international partners

Existing infrastructure will facilitate placements

Large, growing international wound care market



Cross-Selling Opportunities

- Leverage complementary technologies and common call points
- Utilize large combined salesforce

Cross-Selling Opportunities

Increases indications served and expands wound care footprint

Significant industry tailwinds

Complementary treatment therapies

Drive penetration of biologic products